Research programme: calcium channel stabilisers - ARMGO Pharma

Drug Profile

Research programme: calcium channel stabilisers - ARMGO Pharma

Alternative Names: Ryanodine receptor calcium-release channel (RyR) modulators - ARMGO Pharma; Rycals; S 107

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARMGO Pharma
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Diabetes mellitus; Huntington's disease; Post-traumatic stress disorders
  • No development reported Cognition disorders; Musculoskeletal disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cognition-disorders in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA (PO)
  • 17 Aug 2017 Early research in Alzheimer's disease in USA (PO) prior to August 2017 (ARMGO Pharma pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top